Search

  • Contact Us
  • Quick Order
CTS™ DynaMag™ Magnet
Citations & References (2)
Gibco™

CTS™ DynaMag™ Magnet

The CTS™ DynaMag™ Magnet is suitable for use with commercially available sterile blood/culture bags, tubing, and connectors.Benefits:• Ideal for magneticRead more
Have Questions?
Catalog NumberQuantity
121021 Each
Catalog number 12102
Price (MXN)
-
Quantity:
1 Each
The CTS™ DynaMag™ Magnet is suitable for use with commercially available sterile blood/culture bags, tubing, and connectors.

Benefits:
• Ideal for magnetic isolation in closed, sterile blood bags
• Scalable volumes: 50 to 330 mL in static separations and >10 L in continuous flow separations following T-cell expansion protocols
• Residual beads that escape initial magnetic capture are retained on a secondary magnet

Applications:
• Positive isolation of CD3+ T-cells for subsequent stimulation/expansion with CTS™ Dynabeads™ CD3/CD28 and removal of CTS Dynabeads CD3/CD28 following T-cell expansion

The CTS DynaMag Magnet is intended for use with the CTS Dynabeads product portfolio in clinical research such as CTS Dynabeads CD3/CD28 (Cat. No. 40203D).
For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals.
Specifications
For Use With (Equipment)DynaMag™
Product LineCTS, DynaMag
Quantity1 Each
Research CategoryCell Therapy Research
Shipping ConditionRoom Temperature
Unit SizeEach
Contents & Storage
The product contains: CTS DynaMag Magnet

Storage Conditions:
Protect the device from vibration and keep out of direct sunlight.

Frequently asked questions (FAQs)

What are the Gauss levels for the DynaMag-2 and DynaMag-Spin Magnets?

The DynaMag-2 Magnet is 3,500-3,700 minimum Gauss level and the DynaMag-Spin is 3,000-3,500 minimum Gauss level.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What is the standard conversion of Gauss to Tesla units?

1 Tesla is equivalent to 10,000 Gauss. .

How can I clean my DynaMag magnet?

Spray and/or wipe the DynaMag magnet unit with one of the following cleaning agents:

- 70% (v/v) isopropyl alcohol
- 1% (v/v) sodium hypochlorite solution (bleach)
- 0.1 N HCl solution

Do not submerge the magnet unit in aqueous solutions and avoid prolonged exposure to water or aqueous solutions. Clean with a damp cloth and mild detergent when exposed to harsh solvents. Do not autoclave the magnet unit as heating the magnet to above 70 degrees C can destabilize the magnetic material, resulting in loss of magnetic strength.

What is the difference between the DynaMag-2 Magnet (Cat. No. 12321D) and DynaMag-Spin Magnet (Cat. No. 12320D)?

The DynaMag-2 Magnet can hold 16 standard 1.5 mL or 2 mL microcentrifuge tubes, while the DynaMag-Spin Magnet holds up to 6 standard 1.5 mL microcentrifuge tubes.

How can I clean my DynaMag magnet?

Spray and/or wipe the DynaMag magnet unit with one of the following cleaning agents:

- 70% (v/v) isopropyl alcohol
- 1% (v/v) sodium hypochlorite solution (bleach)
- 0.1 N HCl solution

Do not submerge the magnet unit in aqueous solutions and avoid prolonged exposure to water or aqueous solutions. Clean with a damp cloth and mild detergent when exposed to harsh solvents. Do not autoclave the magnet unit as heating the magnet to above 70 degrees C can destabilize the magnetic material, resulting in loss of magnetic strength.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Citations & References (2)

Citations & References
Abstract
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Authors:Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I,
Journal:J Immunother
PubMed ID:19238016
On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of ... More
Simplified process for the production of anti-CD19-CAR-engineered T cells.
Authors:Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M,
Journal:
PubMed ID:23992830
Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia. This therapy involves the transduction of autologous T cells with a viral vector and the subsequent cell expansion. We describe a new, simplified ... More